Influence of biophase distribution and P-glycoprotein interaction on pharmacokinetic-pharmacodynamic modelling of the effects of morphine on the EEG

British Journal of Pharmacology

Volumn 151, Issue 5, 2007, Pages 713-720

  Groenendaal, D ^a,d   Freijer, J ^b   De Mik, D ^a   Bouw, M R ^c   Danhof, M ^a,b   De Lange, E C M ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b LAP and P Consultants BV   (Netherlands)

^c GLAXOSMITHKLINE   (United Kingdom)

^d Astellas Pharma Global Development   (Netherlands)

Author keywords

Biophase distribution; EEG; Morphine; P glycoprotein; Population pharmacokinetic pharmacodynamic modelling

Indexed keywords

ELACRIDAR; MORPHINE;

ANIMAL EXPERIMENT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; ELECTROENCEPHALOGRAM; EXTRACELLULAR FLUID; HYSTERESIS; MALE; MICRODIALYSIS; NONHUMAN; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; PROTEIN INTERACTION; RAT;

ACRIDINES; ALGORITHMS; ANALGESICS, OPIOID; ANIMALS; ELECTROENCEPHALOGRAPHY; EXTRACELLULAR FLUID; MICRODIALYSIS; MODELS, STATISTICAL; MORPHINE; P-GLYCOPROTEIN; RATS; TETRAHYDROISOQUINOLINES; TISSUE DISTRIBUTION;

EID: 34347335653     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1038/sj.bjp.0707258     Document Type: Article

References (30)

1. Bartlett SE, Smith MT (1995). The apparent affinity of morphine-3-glucuronide at mu1-opioid receptors results from morphine contamination: demonstration using HPLC and radioligand binding. Life Sci 57: 609-615.
2. Beal SL, Sheiner LB (1999). NONMEM Users Guide. San Francisco: CA.
3. Bouw MR, Gardmark M, Hammarlund-Udenaes M (2000). Pharmacokinetic- pharmacodynamic modelling of morphine transport across the blood-brain barrier as a cause of the antinociceptive effect delay in rats - a microdialysis study. Pharm Res 17: 1220-1227.
4. Chenel M, Marchand S, Dupuis A, Lamarche I, Paquereau J, Pariat C et al. (2004). Simultaneous central nervous system distribution and pharmacokinetic-pharmacodynamic modelling of the electroencephalogram effect of norfloxacin administered at a convulsant dose in rats. Br J Pharmacol 142: 323-330.
5. Cox EH, Kerbusch T, van der Graaf PH, Danhof M (1998). Pharmacokinetic-pharmacodynamic modeling of the electroence-phalogram effect of synthetic opioids in the rat: correlation with the interaction at the mu-opioid receptor. J Pharmacol Exp Ther 284: 1095-1103.
6. Cox EH, Langemeijer MW, Gubbens-Stibbe JM, Muir KT, Danhof M (1999). The comparative pharmacodynamics of remifentanil and its metabolite, GR90291, in a rat electroencephalographic model. Anesthesiology 90: 535-544.
7. Cox EH, Van Hemert JG, Tukker EJ, Danhof M (1997). Pharmacokinetic- pharmacodynamic modelling of the EEG effect of alfentanil in rats. J Pharmacol Toxicol Methods 38: 99-108.
8. Danhof M, Alvan G, Dahl SG, Kuhlmann J, Paintaud G (2005). Mechanism-based pharmacokinetic-pharmacodynamic modelinga new classification of biomarkers. Pharm Res 22: 1432-1437.
9. de Jong LA, Kramer K, Kroeze MP, Bischoff R, Uges DR, Franke JP (2005). Development and validation of a radioreceptor assay for the determination of morphine and its active metabolites in serum. J Pharm Biomed Anal 39: 964-971.
10. Dingemanse J, Sollie FA, Breimer DD, Danhof M (1988). Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure. J Pharmacokinet Biopharm 16: 203-228.
11. Egan TD, Minto CF, Hermann DJ, Barr J, Muir KT, Shafer SL (1996). Remifentanil versus alfentanil: comparative pharmacokinetics and pharmacodynamics in healthy adult male volunteers. Anesthesiology 84: 821-833.
12. Groenendaal D, Blom-Roosemalen MC, Danhof M, Lange EC (2005). High-performance liquid chromatography of nalbuphine, butorphanol and morphine in blood and brain microdialysate samples: application to pharmacokinetic/ pharmacodynamic studies in rats. J Chromatogr B Analyt Technol Biomed Life Sci 822: 230-237.
13. Groenendaal D, Freijer J, de Mik D, Bouw MR, Danhof M, Lange EC (2007). Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. Br J Pharmacol 151: 701-712 (this issue).
14. Lemmens HJ, Egan TD, Fiset P, Stanski DR (1995). Pharmacokinetic/dynamic assessment in drug development: application to the investigational opioid mirfentanil. Anesth Analg 80: 1206-1211.
15. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL (1998). Effect of GF120918, a potent P-glycoprotein inhibitor, on morphine pharmacokinetics and pharmacodynamics in the rat. Pharm Res 15: 599-605.
16. Letrent SP, Pollack GM, Brouwer KR, Brouwer KL (1999). Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab Dispos 27: 827-834.
17. Loser SV, Meyer J, Freudenthaler S, Sattler M, Desel C, Meineke I et al. (1996). Morphine-6-O-beta-D-glucuronide but not morphine-3-O-beta-D-glucuronide binds to mu-, delta- and kappa-specific opioid binding sites in cerebral membranes. Naunyn Schmiedebergs Arch Pharmacol 354: 192-197.
18. Mahar Doan KM, Humphreys JE, Webster LO, Wring SA, Shampine LJ, Serabjit-Singh CJ et al. (2002). Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs. J Pharmacol Exp Ther 303: 1029-1037.
19. Mandema JW, Veng-Pedersen P, Danhof M (1991). Estimation of amobarbital plasma-effect site equilibration kinetics. Relevance of polyexponential conductance functions. J Pharmacokinet Biopharm 19: 617-634.
20. Mandema JW, Wada DR (1995). Pharmacodynamic model for acute tolerance development to the electroencephalographic effects of alfentanil in the rat. J Pharmacol Exp Ther 275: 1185-1194.
21. Scott JC, Cooke JE, Stanski DR (1991). Electroencephalographic quantitation of opioid effect: comparative pharmacodynamics of fentanyl and sufentanil. Anesthesiology 74: 34-42.
22. Scott JC, Ponganis KV, Stanski DR (1985). EEG quantitation of narcotic effect: the comparative pharmacodynamics of fentanyl and alfentanil. Anesthesiology 62: 234-241.
23. Sheiner LB, Stanski DR, Vozeh S, Miller RD, Ham J (1979). Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clin Pharmacol Ther 25: 358-371.
24. Stanski DR (1992). Pharmacodynamic modeling of anesthetic EEG drug effects. Annu Rev Pharmacol Toxicol 32: 423-447.
25. Tunblad K, Jonsson EN, Hammarlund-Udenaes M (2003). Morphine blood-brain barrier transport is influenced by probenecid co-administration. Pharm Res 20: 618-623.
26. Upton RN, Huang YF, Mather LE, Doolette DJ (1999). The relationship between the myocardial kinetics of meperidine and its effect on myocardial contractility: model-independent analysis and optimal regional model. J Pharmacol Exp Ther 290: 694-701.
27. Upton RN, Ludbrook GL, Grant C, Doolette DJ (2000). The effect of altered cerebral blood flow on the cerebral kinetics of thiopental and propofol in sheep. Anesthesiology 93: 1085-1094.
28. Wauquier A, Bovill JG, Sebel PS (1984). Electroencephalographic effects of fentanyl-, sufentanil- and alfentanil anaesthesia in man. Neuropsychobiology 11: 203-206.
29. Wauquier A, De Ryck M, Van den Broeck W, Van Loon J, Melis W, Janssen P (1988). Relationships between quantitative EEG measures and pharmacodynamics of alfentanil in dogs. Electroencephalogr Clin Neurophysiol 69: 550-560.
30. Young GA, Khazan N (1984). Differential neuropharmacological effects of mu, kappa and sigma opioid agonists on cortical EEG power spectra in the rat. Stereospecificity and naloxone antagonism. Neuropharmacology 23: 1161-1165.